Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016

Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need.  This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.